Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: Direct quantitative PCR for ALU repeats

Clinical Chemistry

Volumn 52, Issue 6, 2006, Pages 1062-1069

  Umetani, Naoyuki ^a   Kim, Joseph ^a   Hiramatsu, Suzanne ^a   Reber, Howard A ^b   Hines, Oscar J ^b   Bilchik, Anton J ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; DNA FRAGMENT;

ALU SEQUENCE; ANIMAL TISSUE; ARTICLE; ARTIFACT; CANCER; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DNA PURIFICATION; GENE AMPLIFICATION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE REPEAT; PERIAMPULLARY CANCER; POLYMERASE CHAIN REACTION; SERUM;

AGED; AMPULLA OF VATER; CARCINOMA, PANCREATIC DUCTAL; COLORECTAL NEOPLASMS; COMMON BILE DUCT NEOPLASMS; DNA; DNA FRAGMENTATION; DUODENAL NEOPLASMS; FEMALE; HUMANS; MALE; PANCREATIC NEOPLASMS; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33646935703     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.068577     Document Type: Article

References (31)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Frebourg T, Bercoff E, Manchon N, Senant J, Basuyau JP, Breton P, et al. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer: a prospective study of 866 patients. Cancer 1988;62:2287-90.
3. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 2001;47:624-30.
4. Taback B, Hoon DS. Circulating nucleic acids and proteomics of plasma/serum: clinical utility. Ann N Y Acad Sci 2004;1022:1-8.
5. Taback B, Hoon DS. Circulating nucleic acids in plasma and serum: past, present and future. Curr Opin Mol Ther 2004;6:273-8.
6. Fujimoto A, O'Day SJ, Taback B, Elashoff D, Hoon DS. Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res 2004;64:4085-8.
7. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res 2003;63:3966-8.
8. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998;17:89-97.
9. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65.
10. Hwu HR, Roberts JW, Davidson EH, Britten RJ. Insertion and/or deletion of many repeated DNA sequences in human and higher ape evolution. Proc Natl Acad Sci U S A 1986;83:3875-9.
11. Gu Z, Wang H, Nekrutenko A, Li WH. Densities, length proportions, and other distributional features of repetitive sequences in the human genome estimated from 430 megabases of genomic sequence. Gene 2000;259:81-8.
12. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
13. Smit AF. The origin of interspersed repeats in the human genome. Curr Opin Genet Dev 1996;6:743-8.
14. Jurka J. Repeats in genomic DNA: mining and meaning. Curr Opin Struct Biol 1998;8:333-7.
15. Sorenson GD. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin Cancer Res 2000;6:2129-37.
16. Uemura T, Hibi K, Kaneko T, Takeda S, Inoue S, Okochi O, et al. Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients. J Gastroenterol 2004;39:56-60.
17. Lindforss U, Zetterquist H, Papadogiannakis N, Olivecrona H. Persistence of K-ras mutations in plasma after colorectal tumor resection. Anticancer Res 2005;25:657-61.
18. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-50.
19. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999;18:65-73.
20. Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004;10:5981-7.
21. Herrera LJ, Raja S, Gooding WE, El-Hefnawy T, Kelly L, Luketich JD, et al. Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem 2005;51:113-8.
22. Taback B, O'Day SJ, Hoon DS. Quantification of circulating DNA in the plasma and serum of cancer patients. Ann N Y Acad Sci 2004;1022:17-24.
23. Holdenrieder S, Stieber P, Chan LY, Geiger S, Kremer A, Nagel D, et al. Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR. Clin Chem 2005;51:1544-6.
24. Umetani N, Hiramatsu S, Hoon DSB. Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. CNAPSIV. Ann N Y Acad Sci 2006;in press.
25. Lam NY, Rainer TH, Chan LY, Joynt GM, Lo YMD. Time course of early and late changes in plasma DNA in trauma patients. Clin Chem 2003;49:1286-91.
26. Chan KC, Zhang J, Hui AB, Wong N, Lau TK, Leung TN, et al. Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem 2004;50:88-92.
27. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003;124:544-60.
28. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-71.
29. Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg 1998;228:59-63.
30. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990;66:56-61.
31. Westerdahl J, Andren-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer-local or hepatic? Hepatogastroenterology 1993;40:384-7.